Pharmacology of opioids in the treatment of chronic pain syndromes

Pain Physician

Volumn 14, Issue 4, 2011, Pages

  Vallejo, Ricardo ^a,d,e   Barkin, Robert L ^b,f   Wang, Victor C ^c  

^a MILLENNIUM PAIN CENTER   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d ILLINOIS STATE UNIVERSITY   (United States)

^e CENTRO MÉDICO TEKNON   (Spain)

^f NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Codeine; Dynorphins; Endorphins; Enkephalins; Fentanyl; Hydrocodone; Hydromorphone; Intractable pain; Methadone; Morphine; Narcotics; Opioid interactions; Opioid metabolism; Oxycodone; Oxymorphone; Pharmacology; Propoxyphene; Tramadol

Indexed keywords

BUPRENORPHINE; CODEINE; DELTA OPIATE RECEPTOR; FENTANYL; HYDROCODONE; HYDROMORPHONE; KAPPA OPIATE RECEPTOR; LEVORPHANOL; METHADONE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; NALBUPHINE; NARCOTIC ANALGESIC AGENT; OPIATE AGONIST; OPIATE ANTAGONIST; OXYCODONE; OXYMORPHONE; PETHIDINE; TAPENTADOL; TRAMADOL;

AGITATION; BINDING AFFINITY; BRADYCARDIA; CHRONIC PAIN; COMA; CONSTIPATION; CONVULSION; CYANOSIS; DELIRIUM; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DYSPHORIA; ELECTROENCEPHALOGRAPHY; HUMAN; HYPERPYREXIA; HYPERTENSION; HYPOTENSION; LEARNING DISORDER; LOW DRUG DOSE; MINOR AFFECTIVE DISORDER; MIOSIS; MYOCLONUS; NAUSEA; NEUROPATHIC PAIN; NEUROPHARMACOLOGY; NEUROTOXICITY; NONHUMAN; PRURITUS; QT PROLONGATION; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TACHYCARDIA; URINE RETENTION; VERTIGO; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANALGESICS, OPIOID; CHRONIC DISEASE; HUMANS; PAIN; PRACTICE GUIDELINES AS TOPIC;

EID: 79960886001     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (170)

1. Schatman ME. Pain medicine: Business or profession? Medscape Neurology 2011. www.medscape.com/viewarticle/742692. Accessed 5/20/2011.
2. Smith HS, Barkin RL. Fibromyalgia syndrome: A discussion of the syndrome and pharmacotherapy. Am J of Therapeutics 2010;17:419-439.
3. Barkin, RL, Iusco A, Barkin S. Weiner's Pain Management: A Practical Guide for Clinicians. 7th Ed. CRC Press, New York, 2006, pp 779-794.
4. Barkin RL. Incorporation of science and clinical medicine in the process of patient-specific and patient-centered, patient focused prescribing and personalize patient care. Pain Med Network 2008; 23:4-9.
5. Foley KM. Opioids. Neurol Clin 1993; 11:503-522.
6. Jaffe JH, Martin WR. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. Pergamon Press, New York, 1990, pp 485-521.
7. Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 1988; 244:1067-1080.
8. Leone P, Pocock D, Wise RA. Morphine dopamine interaction: Ventral tegmental morphine increases nucleus accumbens dopamine release. Pharmacol Biochem Beh 1991; 39:469-472.
9. Matthews RT, German DC. Electro physiological evidence for excitation of rat ventral tegmental area dopaminergic neurons by morphine. Neuroscience 1984; 11:617-626.
10. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The delta-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992; 89:12048-12052.
11. Evans CJ, Erdelyi E, Weber E, Barchas JD. Identification of pro-opiomelanocortin-derived peptides in the human adrenal medulla. Science 1992; 258:1952-1955.
12. Chen Y, Fan Y, Liu J, Mestek A, Tian M, Kozak CA, Yu L. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett 1994; 347:279-283.
13. Mollereau C, Parmetier M, Mailleux P, Butour JL, Moisand C, Chalon P, Caput D, Vassart G, Meunier JC. ORL1, a novel member of the opioid receptor family. Cloning, functional expression, and localization. FEBS Lett 1994; 341:33-38.
14. Anton B, Fein J, To T, Li X, Silberstein L, Evans CJ. Immunohistochemical localization of ORL-1 in the central nervous system of the rat. J Comp Neurol 1996; 368:229-251.
15. Paul D, Bodnar RJ, Gistrak MA, Pasternak GW. Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur J Pharmacol 1989; 168:307-314.
16. Lacoste A, Evans CJ. The Delta Receptor. Marcel Dekker, New York, 2004, pp 15-30.
17. Wollemann M, Benyhe S, Simon J. The kappa-opioid receptor: Evidence for the different subtypes. Life Sciences 1993; 52:599-611.
18. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: Biology and function. Ann Rev Neurosci 1984; 7:223-255.
19. Capogna M, Gähwiler BH, Thompson SM. Mechanism of mu-opioid receptormediated presynaptic inhibition in the rat hippocampus in vitro. J Physiol 1993; 470:539-558.
20. Werz MA, MacDonald RL. Opioid peptides decrease calcium-dependent action potential duration of mouse dorsal root ganglion neurons in cell culture. Brain Research 1982; 239:315-321.
21. Vaughan CW, Christie MJ. Presynaptic inhibitory action of opioids on synaptic transmission in the rat periaqueductal grey in vitro. J Physiol 1997; 498:463-467.
22. Bradford HF, Crowder JM, White EJ. Inhibitory actions of opioid compounds on calcium fluxes and neurotransmitter release from mammalian cerebral cortical slices. Br J Pharmacol 1986; 88:87-93.
23. Inturrisi CE, Lipman AG. Bonica's Management of Pain. 4th Ed. Lippincott, Williams & Wilkins, Philadelphia, 2009, pp 1172-1186.
24. Jhamandas KH. Opioid-neurotransmitter interactions: Significance in analgesia, tolerance and dependence. Prog Neuro-Psychopharmacol Biol Psychiatr 1984; 8:565-570.
25. Pepper CM, Henderson G. Opiates and opioid peptides hyperpolarize locus coeruleus neurons in vitro. Science 1980; 209:394-395.
26. Werz MA, MacDonald RL. Opioid peptides selective for mu-and delta-opiate receptors reduce calcium-dependent action potential duration by increasing potassium conductance. Neurosci Lett 1983; 42:173-178.
27. Pan ZZ. κ-Opioid receptor-mediated enhancement of the hyperpolarization-activated current (Ih) through mobilization of intracellular calcium in rat nucleus raphe magnus. J Physiol 2003; 583:765-775.
28. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest 2010; 120:3779-3787.
29. Thompson JW. Opioid peptides. Br Med J 1984; 288:259-261.
30. Schlaepfer TE, Strain EC, Greenberg BD, Preston KL, Lancaster E, Bigelow GE, Barta PE, Pearlson GD. Site of opioid action in the human brain: Mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatr 1998; 155:470-473.
31. Simon EJ, Hiller JM. The opiate receptors. Ann Rev Pharmacol Toxicol 1978; 18:371-394.
32. McDonald J, Lambert DC. Opioid receptors. CEACCP 2005; 5:22-25.
33. Coda BA. Clinical Anesthesia. 6th Ed. Lippincott Williams & Wilkins, Philadelphia, 2009, pp 464-497.
34. Trivedi M, Shaikh S, Gwinnut C. Pharmacology of opioids. Update in Anaesthesia 2011, pp 118-124. www.worldanesthesia. org.
35. Gordon DB, Stevenson KK, Griffie J, Muchka S, Rapp C, Ford-Roberts K. Opioid equianalgesic calculations. J Pall Med 2005; 2:209-218.
36. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain 2003; 19:286-297.
37. Kupers RC, Konings H, Adriaensen H, Gybels JM. Morphine differentially affects sensory and affective pain ratings in neurogenic and diopathic forms of pain. Pain 1991; 47:5-12.
38. Aner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988; 33:11-23.
39. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11:S133-153.
40. Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: Actions and mechanisms. Med Res Rev 2005; 25:521-544.
41. van Dorp EL, Romberg R, Sarton E, Bovill JG, Dahan A. Morphine-6-glucuronide: Morphine's successor for postoperative pain relief? Anesth Analg 2006; 102:1789-1797.
42. Jenkins AJ. Pharmacokinetics of specific drugs. In Karch SB (ed). Pharmacokinetics and Pharmacodynamics of Abused Drugs. CRC Press, Boca Raton, 2008, pp 25-64.
43. Kerr B, Hill H, Coda B, Calogero M, Chapman CR, Hunt E, Buffington V, Mackie A. Concentration-related effects of morphine on cognition and motor control in human subjects. Neuropsychopharmacology 1991; 5:157-166.
44. Friswell J, Phillips C, Holding J, Morgan CJ, Brandner B, Curran HV. Acute effects of opioids on memory functions of healthy men and women. Psychopharmacology 2008; 198:243-250.
45. Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. J Pain Symptom Manage 2000; 19:200-208.
46. Janicki PK. Pharmacology of morphine metabolites. Curr Pain Headache Rep 1997; 1:264-270.
47. Lötsch J, Stockman A, Kobal G, Brune K, Waibel R, Schmidt N, Geisslinger G. Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers. Clin Pharmacol Therapeut 1996; 60:316-325.
48. Vater M, Smith G, Aherne GW, Aitkenhead AR. Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers. Br J Anaesth 1984; 56:821-827.
49. Gharibo C. Managing chronic moderate to severe pain-Embeda (Morphine sulfate and naltrexone hydrochloride) extended release capsules for oral use. US Neurol 2010; 6:18-22.
50. Carlozzi AF, Fornari FA, Siwicki DM, Barkin RL, Nafziger AN, Woodcock M, Johnson C, Rodriguez AJ, Bertino JS, Bauer GB, Michner E, Aronoff G, Empting LD. Urine Drug Monitoring: Opioids. McMahon Publishing Group, 2009.
51. Quigley C: Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2002; 1:CD003447
52. Sathyan G, Xu E, Thipphawong J, Gupta SK. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food. BMC Clin Pharmacol 2007; 7:2-9.
53. Inturrisi CE: Clinical pharmacology of opioids for pain. Clin J Pain 2002; 8:S3-13.
54. Sarhill N, Walsh D, Nelson KA. Hydromorphone: Pharmacology and clinical applications in cancer patients. Support Care Cancer 2001; 9:84-96.
55. Kumar P, Sunkaraneni S, Sirohi S, Dighe SV, Walker EA, Yoburn BC. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation. Eur J Pharmacol 2008; 597:39-45.
56. Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol 1981; 21:152-156.
57. Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 1988; 38:877-880.
58. Wright AW, Mather LE, Smith MT. Hydromophone-3-glucuronide: A more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69: 409-420.
59. Guay DR. Use of oral oxymorphone in the elderly. Consult Pharm 2007; 22:417-430.
60. Thwaites D, McCann S, Broderick P. Hydromophone neuroexcitation. J Palliat Med 2004;7:545-550.
61. Warolin C. Pierre-Jean Robiquet. Rev Hist Pharm (Paris) 1999; 47:97-110. [French]
62. Smith HS. Opioid metabolism. Mayo Clin Proc 2009; 84:613-624.
63. Thorn CF, Klein TE, Altman RB. Codeine and morphine pathway. Pharmacogenet Genomics 2009; 19:556-558.
64. Rossi S, (ed). Australian Medicines Handbook. Australian Medicines Handbook, Adelaide, 2004.
65. Vree TB, van Dongen RT, Koopman-Kimenai PM. Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract 2000; 54:395-398.
66. Srinivasan V, Wielbo D, Tebbett IR. Analgesic effects of codeine-6-glucuronide after intravenous administration. Eur J Pain 1997; 1:185-190.
67. Reynolds L, Rauck R, Webster L, DuPen S, Heinze E, Portenoy R, Katz N, Charapata S, Wallace M, Fisher DM. Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. Pain 2004; 10:182-188.
68. Lichtor JL, Sevarino FB, Joshi GP, Busch MA, Nordbrock E, Ginsberg B. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg 1999; 89:732-738.
69. Kim KS, Simon L. Transport mechanisms in oral transmucosal drug delivery: Implications for pain management. Math Biosci 2011; 229:93-100.
70. Vasisht N, Gever LN, Tagarro I, Finn AL. Evaluation of the single-and multipledose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. J Clin Pharmacol 2010; 50:785-791.
71. Grape S, Schug SA, Lauer S, Schug BS. Formulations of fentanyl in the management of pain. Drugs 2010; 70:57-72.
72. Nelson L, Schwaner R. Transdermal fentanyl: Pharmacology and toxicology. J Med Toxicol 2009; 5:230-241.
73. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53:109-138.
74. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28:497-504.
75. Tegeder I, Lötsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999; 37:17-40.
76. Prommer E. Levorphanol: The forgotten opioid. Support Care Cancer 2007; 15:259-264.
77. Zhang A, Xiong W, Bidlack JM, Hilbert JE, Knapp BI. Wentland MP, Neumeyer JL. 10-Ketormorphinan and 3-substituted-3-desoxymorphian analogues as mixed kappa and micro opioid ligands: Synthesis and biological evaluation of their binding aflinity at opioid receptors. J Med Chem 2004; 47:165-174.
78. Wang Y, Li JG. Huang P, Xu W, Liu-Chen LY. Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: Adenylyl cyclase superactivatian is independent of agonist-induced phosphorylation, desensitization, internalization, and down-regulation. J Pharmacol Exp Ther 2003; 307:1127-1134.
79. Tive L, Ginsberg K, Pick CG, Pasternak GW. Kappa 3 receptors and levorphanolinduced analgesia. Neuropharmacology 1992; 31:851-856.
80. Moulin DE, Ling GS, Pasternak GW. Unidirectional analgesic cross-tolerance between morphine and levorphanol in the rat. Pain 1988;33:233-239.
81. Blake AD, Bat G, Li S, Freeman JC, Reisine T. Differential agonist regulation of the human kappa-opioid receptor. J Neurochem 1997; 68:1846-1852.
82. Stringer M, Makin MK, Miles J, Morley JS. D-morphine, but not L-morphine, has low micromolar affinity for the noncompetitive N-methyl-D-aspartate site in rat forebrain. Possible clinical implications for the management of neuropathic pain. Neurosci Lett 2000; 295:21-24.
83. McNulty JP. Can levorphanol be used like methadone for intractable refractory pain? J Palliat Med 2007; 10:293-296.
84. Labella FS, Pinsky C, Havlicek V. Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity. Brain Res 1979; 174:263-271.
85. Lomenzo SA, Rhoden JB, Izenwasser S, Wade D, Kopajtic T, Katz JL, Trudell ML. Synthesis and biological evaluation of meperidine analogues at monoamine transporters. J Med Chem 2005; 48:1336-1343.
86. Marinella MA. Meperidine-induced generalized seizures with normal renal function. South Med J 1997; 90:556-558.
87. Armstrong SC, Wynn GH, Sandson NB. Pharmacokinetic drug interactions of synthetic opiate analgesics. Psychosomatics 2009; 50:169-176.
88. Sporer KA. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 1996; 15:8-29.
89. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005; 95:434-441.
90. Seifert CF, Kennedy S. Meperidine is alive and well in the new millennium: Evaluation of meperidine usage patterns and frequency of adverse drug reactions. Pharmacotherapy 2004; 24:776-783.
91. Wainer BH, Wung WE, Hill JH, Fitch FW, Fried J, Rothberg RM. The production and characterization of antibodies reactive with meperidine. J Pharmacol Exp Ther 1976; 197:734-743.
92. Latta KS, Ginsberg B, Barkin RL. Meperidine: A critical review. Am J of Ther 2002; 9:53-58.
93. Szeto HH, Lovelace JL, Fridland G, Soong Y, Fasolo J, Wu D, Desiderio DM, Schiller PW. In vivo pharmacokinetics of selective mu-opioid peptide agonists. J Pharmacol Exp Ther 2001; 298:57-61.
94. Ikeda T, Kurz A, Sessler DI, Go J, Kurz M, Belani K, Larson M, Bjorksten AR, Dechert M, Christensen R. The effect of opioids on thermoregulatory responses and the special antishivering action of meperidine. Ann N Y Acad Sci 1997; 813:792-798.
95. Stambaugh JE, Wainer IW, Sanstead JK, Hemphill DM. The clinical pharmacology of meperidine-comparison of routes of administration. J Clin Pharmacol 1976; 16:245-256.
96. Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm 2009; 66:825-833.
97. Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. QT interval prolongation:Prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundam Clin Pharmacol 2011; 25:503-510.
98. Heppe DB, Haigney MC, Kranz MJ. The effect of oral methadone on the QTc interval in advanced cancer patients: A prospective pilot study. J Palliat Med 2010; 13:638-639.
99. Huh B, Park CH. Retrospective analysis of low-dose methadone and QTc prolongation in chronic pain patients. Korean J Anesthesiol 2010; 58:338-343.
100. Burgess FW, Krantz MJ, Barkin RL. Methadone: Unintended mortality due to overdose and arrhythmia. Pain Med (Special Edition) 2007; 5:25-31.
101. Fredheim OM, Moksnes K, Borchgrevink PC, Daasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 2008; 52:879-889.
102. Fredheim OM, Borchgrevink PC, Klepstad P, Kaasa S, Dale O. Long term methadone for chronic pain: A pilot study of pharmacokinetic aspects. Eur J Pain 2007; 11:599-604.
103. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113-130.
104. Xiao Y, Smith RD, Caruso FS, Kellar KJ. Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther 2001; 299:366-371.
105. Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P. Opioids and the management of chronic severe pain in the elderly: Consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 8:287-313.
106. Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 2008; 9:595-612.
107. Denson DD, Concilus RR, Gregg RV, Crews JC. The correlation between predicted and measured patient specific analgesic concentrations after intravenous titration: A guide for initial maintenance requirements with methadone. J Clin Pharmacol 1990; 30:1049-1054.
108. Fingerhut LA. Increases in poisoning and methadone-related deaths: United States, 1999-2005. NCHS Heath & Stats February 2008. http://cdc.gove/nchs/data/hestat/poisoning/poisoning.pdf. Accessed 02/14/2011.
109. Gouldin WM, Kennedy DT, Small RE. Methadone: History and recommendations for use in analgesia. APS Bulletin 2000; 10:1-11www.ampainsoc.org/pub/bulletin/sep00/upda1.htm. Accessed 01/29/2011.
110. Cone E, Darwin W, Gorodetzky C, Tan T. Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog. Drug Metab Dispos 1978; 6:488-493.
111. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48:2165-2171.
112. Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, Cheung SW, Otton SV, Somer G, Sellers EM. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 1997; 281:103-108.
113. Hutchinson MR, Menelaou A, Foster DJR, Coller JK, Somogyi AA. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 2003; 57:287-297.
114. Daly A, Brockmoller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
115. Kroemer HK, Eichelbaum M. "It's the genes, stupid. " Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995; 56:2285-2298.
116. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clin Pharmacol Ther 2006; 79:461-479.
117. Kailko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD. Pharmacokinetic-pharmadynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996; 59:52-61.
118. Pöyhiä R, Vainio A, Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993; 8:63-67.
119. Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R. Normal-release and controlled-release oxycodone: Pharmacokinetics, pharmacodynamics and controversy. Support Care Cancer 2003; 11:84-92.
120. Duttaroy A, Yoburn BC. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 1995; 82:1226-1236.
121. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT. Oxycodone and morphine have distinctly different pharmacological profiles: Radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007; 132:289-300.
122. Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997; 73:151-157.
123. Olesen AE, Upton R, Foster DJ, Staahl C, Christrup LL, Arendt-Nielsen L, Drewes AM. A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia. Clin Pharmacokinet 2010; 49:817-827.
124. Kok GB, Pye CC, Singer RD, Scammells PJ. Two-sept iron(0)-mediated N-demethylation of N-methyl alkaloids. J Org Chem 2010; 75:4806-4811.
125. Sloan P. Review of oral oxymorphone in the management of pain. Therapeut Clin Risk Manage 2008; 4:777-787.
126. Sinatra RS, Lodge K, Sibert K, Chung KS, Chung JH, Parker A Jr, Harrison DM. A comparison of morphine, meperidine, and oxymorphone as utilized in patientcontrolled analgesia following cesarean delivery. Anesthesiology 1989; 70:585-590.
127. Sloan PA, Slatkin NE, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: A pilot study. Supp Care Cancer 2005; 13:57-65.
128. Adams MP, Ahdieh H. Single-and multiple-dose pharmacokinetic and doseproportionality study of oxymorphone immediate-release tablets. Drugs R D 2005; 6:91-99.
129. Gimbel J, Ahdieh H. The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg 2004; 99:1472-1477.
130. Guay DR. Oral oxymorphone extendedrelease. Consult Pharm 2010; 25:816-828.
131. Matsumoto AK. Oral extended-release oxymorphone: A new choice for chronic pain relief. Expert Opin Pharmacother 2007; 8:1515-1527.
132. Adams M, Pieniaszek HJ Jr, Gammaitoni AR, Ahdieh H. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol 2005; 45:337-345.
133. Sloan PA, Barkin RL. Oxymorphone and oxymorphone extended release: A pharmacotherapeutic review. J Opioid Manage 2008; 4:3131-144.
134. Uysal HY, Takmaz SA, Yaman F, Baltaci B, Baar H. The efficacy of intravenous paracetamol versus tramadol for postoperative analgesia after adenotonsillectomy in children. J Clin Anesth 2011; 23:53-57.
135. Sansone RA, Sansone LA. Tramadol: Seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry (Edgmont) 2009; 6:17-21.
136. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinetics 2004; 3:879-923.
137. Katz W, Barkin RL. Dilemmas in chronic/persistent pain management. Am J Ther 2008; 15:256-264.
138. Barkin RL. Extended-release tramadol (ULTRAM®ER): A pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain. Am J Ther 2008; 15:157-166.
139. Wade WE, Spruill WJ. Tapentadol hydrochloride: A centrally acting oral analgesic. Clin Ther 2009; 31:2804-2818.
140. Barkin RL. Tapentadol: A pharmacotherapeutic focused brief review. Pain Med Network 2009; 24:8,11.
141. Tzschentke TM, De Vry J, Terlinden R, Hennies H, Lange C, Strassburger W, Haurand M, Kolb J, Schneider J, Buschmann H, Finkam M, Jahnel U, Friderichs E. Tapentadol hydrochloride: Analgesic mu-opioid receptor agonist noradrenaline reuptake inhibitor. Drugs Future 2006; 31:1053-1061.
142. West JC, Kosten TR, Wilk J, Svikis D, Triffleman E, Rae DS, Narrow WE, Duffy FF, Regier DA. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict 2004; 13:S9-S16.
143. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Buris A, Taylor RS. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Heath Technol Assess 2007; 11:1-171.
144. Soyka M, Apelt SM, Lieb M, Wittchen HU. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: A nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006; 26:657-660.
145. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197:517-532.
146. Lutfy K, Cowan A. Buprenorphine: A unique drug with complex pharmacology. Curr Neuropharmacol 2004; 2:395-402.
147. Jasinski DR, Haertzen CA, Henningfield JE, Johnson RE, Makhzoumi HM, Miyasato K. Progress Report of the NIDA Addiction Research Center. NIDA Research Monograph, Rockville, 1982; pp 45-52.
148. Bullingham RE, McQuay HJ, Moore RA. Clinical pharmacokinetics of narcotic agonist-antagonist drugs. Clin Pharmacokinet 1983; 8:332-343.
149. Johnson RE, Fudal PJ, Payne R. Buprenorphine: Considerations for pain management. J Pain Symptom Manage 2005; 29:297-326.
150. Bullingham RE, McQuay HJ, Moore A, Bennett MR. Buprenorphine kinetics. Clin Pharmacol Ther 1980; 28:667-672.
151. Watson PJQ, McQuay HJ, Bullingham RE, Allen MC, Moore RA. Single-dose comparison of buprenorphine 0.3 and 0.6mg i.v. given after operation: Clinical effects and plasma concentration. Br J Anaesth 1982; 54:37-43.
152. Walter DS, Inturrisi CE. Absorption, distribution, metabolism, and excretion of buprenorphine in animals and humans. In: Cowan A, Lewis JW (eds). Buprenorphine: Combatting Drug Abuse with a Unique Opioid. Wiley-Liss, New York, 1995, pp 113-135.
153. Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in n-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997; 60:1953-1964.
154. Kobayashi K, Yamamoto T, Chiba K, Tani M, Shimada N, Ishizaki T, Kuroiwa Y. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 1998; 26:818-821.
155. Mendelson J, Upton RA, Everhart ET, Jacob P 3rd, Jones RT. Bioavailability of sublingual buprenorphine. J Clin Pharmacol 1997; 37:31-37.
156. Everhart ET, Cheung P, Shwonek P, Zabel K, Tisdale EC, Jacob P, Mendelson J, Jones RT. Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: Application to pharmacokinetics of sublingual buprenorphine. Clin Chem 1997; 43:2292-2302.
157. Bullingham RE, McQuay HJ, Dwyer D, Allen MC, Moore RA. Sublingual buprenorphine used postoperatively: Clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol 1981; 12:117-122.
158. Bullingham RE, McQuay HJ, Porter EJ, Allen MC, Moore RA. Sublingual buprenorphine used postoperatively: Tenhour plasma drug concentration analysis. Br J Clin Pharmacol 1982; 13:665-673.
159. Reidenberg B, El-Tahtawy A, Munera C, Cipriano A, Tonelli A, Reder R. Absolute bioavailability of a novel buprenorphine transdermal system (BTDS) applied for 7 days. J Clin Pharmacol 2001; 41:1026.
160. Reidenberg B, El-Tahtawy A, Munera C, Cipriano A, Tonelli A, Reder R. Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to 7 days. J Clin Pharmacol 2001; 41:1027.
161. Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther 2005; 12:379-384.
162. Chen JC, Smith ER, Cahill M, Cohen R, Fishman JB. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol, and nalbuphine. Life Sci 1993; 52:389-396.
163. Schmidt WK, Tam SW, Shotzberger GS, Smith Jr DW, Clark R, Vernier VG. Nalbuphine. Drug Alcohol Dep 1985; 14:339-362.
164. DeSouza EB, Schmidt WK, Kuhar MJ. Nalbuphine: An autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther 1988; 244:391-402.
165. Gunion MW, Marchionne AM, Anderson CTM. Use of the mixed agonist-antagonist nalbuphine in opioid based analgesia. Acute Pain 2004; 6:29-39.
166. Beaver WT, Feise GA. A comparison of the analgesic effect of intramuscular nalbuphine and morphine in patients with postoperative pain. J Pharmacol Exp Ther 1978; 204:487-496.
167. Errick JK, Heel RC. Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 1983; 26:191-211.
168. Lo MW, Lee FH, Schary WL, Whitney CC. The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects. Eur J Clin Pharmacol 1987; 33:297-301.
169. Jaillon P, Gardin ME, Lecocq B, Richard MO, Meignan S, Blondel Y, Grippat JC, Bergnieres J, Vergnoux O. Pharmacokinetics of nalbuphine in infants, young healthy volunteers, and elderly patients. Clin Pharmacol Ther 1989; 46:226-233.
170. Gutstein HB, Akil H. Opioid analgesics. In: Hardman JG, Limbird LE (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. McGraw-Hill, New York, 2001, pp 569-619.